ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYH2059

A development code. Also written as “SYH2059 Tablets”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since May 7, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since May 7, 2026Mar 29, 2026Dec 31, 2026phase 1 · NCT07510958

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 29, 2026First study: phase 1 study in Healthy ParticipantsFirst studyNCT07510958 · 84 planned
  2. May 7, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07600021 · 156 planned

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07510958
  2. Oct 30, 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07600021

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07600021Idiopathic Pulmonary Fibrosis2Not yet recruitingOct 30, 2027156
NCT07510958Healthy Participants1Not yet recruitingDec 31, 202684

How it is read

Names in the registry

  • “SYH2059 Tablets”, 1 entry
  • “SYH2059”, 1 entry

Codes read as this program: SYH2059.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.